OTCMKTS:EMISEmisphere Technologies Stock Price, Forecast & News

$5.50

-0.33 (-5.66 %)

(As of 05/27/2020 04:00 PM ET)

Add

Compare

Today's Range

$5.28

Now: $5.50▼

$5.75

50-Day Range

$5.10

MA: $5.85▼

$6.57

52-Week Range

$3.88

Now: $5.50▼

$11.23

Volume14,775 shs

Average Volume52,516 shs

Market Capitalization$462.15 million

P/E RatioN/A

Dividend YieldN/A

Beta1.65

Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Emisphere Technologies.

2.6 Community Rank

Outperform Votes
Emisphere Technologies has received 80 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Emisphere Technologies has received 76 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Emisphere Technologies has received 51.28% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Emisphere Technologies and other stocks. Vote “Outperform” if you believe EMIS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EMIS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Emisphere Technologies does not currently pay a dividend.
Dividend Growth
Emisphere Technologies does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Emisphere Technologies insiders have not sold or bought any company stock.
Percentage Held by Insiders
72.90% of the stock of Emisphere Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 0.03% of the stock of Emisphere Technologies is held by institutions.

0.0 Earnings and Valuation

Overall Beat the Market Rank^™

0.72 out of 5 stars

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:EMIS

Previous Symbol

CUSIPN/A

CIK805326

Webwww.emisphere.com

Phone973-532-8000

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees6

Outstanding Shares84,028,000

Market Cap$462.15 million

Next Earnings DateN/A

OptionableNot Optionable

Receive EMIS News and Ratings via Email

Sign-up to receive the latest news and ratings for EMIS and its competitors with MarketBeat's FREE daily newsletter.

Emisphere Technologies (OTCMKTS:EMIS) Frequently Asked Questions

How has Emisphere Technologies' stock been impacted by COVID-19 (Coronavirus)?

Emisphere Technologies' stock was trading at $6.45 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EMIS stock has decreased by 14.7% and is now trading at $5.50. View which stocks have been most impacted by Coronavirus.

How were Emisphere Technologies' earnings last quarter?

Emisphere Technologies, Inc. (OTCMKTS:EMIS) announced its earnings results on Friday, May, 12th. The company reported $0.04 earnings per share (EPS) for the quarter. The firm earned $0.22 million during the quarter. View Emisphere Technologies' earnings history.

Has Emisphere Technologies been receiving favorable news coverage?

Headlines about EMIS stock have trended somewhat positive on Wednesday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Emisphere Technologies earned a news sentiment score of 1.4 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news aboutEmisphere Technologies.

Who are some of Emisphere Technologies' key competitors?

Some companies that are related to Emisphere Technologies include Madrigal Pharmaceuticals (MDGL), Ironwood Pharmaceuticals (IRWD), Pacira Biosciences (PCRX), Aurinia Pharmaceuticals (AUPH), Corcept Therapeutics (CORT), Eidos Therapeutics (EIDX), Xencor (XNCR), IGM Biosciences (IGMS), Theravance Biopharma (TBPH), Arvinas (ARVN), Dicerna Pharmaceuticals (DRNA), Heron Therapeutics (HRTX), Zogenix (ZGNX), Arcus Biosciences (RCUS) and Zymeworks (ZYME). View all competitors.

What other stocks do shareholders of Emisphere Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emisphere Technologies investors own include Novo Nordisk A/S (NVO), DelMar Pharmaceuticals (DMPI), Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Capricor Therapeutics (CAPR), Heat Biologics (HTBX), Rigel Pharmaceuticals (RIGL), Superconductor Technologies (SCON), Arbutus Biopharma (ABUS) and Aurora Cannabis (ACBFF).

Who are Emisphere Technologies' key executives?

Emisphere Technologies' management team includes the following people:

Mr. Alan L. Rubino, CEO, Pres & Director (Age 64)
Mr. Alan V. Gallantar CPA, Interim Chief Financial Officer (Age 61)

What is Emisphere Technologies' stock symbol?

Emisphere Technologies trades on the OTCMKTS under the ticker symbol "EMIS."

How do I buy shares of Emisphere Technologies?

Shares of EMIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Emisphere Technologies' stock price today?

One share of EMIS stock can currently be purchased for approximately $5.50.

How big of a company is Emisphere Technologies?

Emisphere Technologies has a market capitalization of $462.15 million. Emisphere Technologies employs 6 workers across the globe.

What is Emisphere Technologies' official website?

The official website for Emisphere Technologies is www.emisphere.com.

How can I contact Emisphere Technologies?

Emisphere Technologies' mailing address is 4 BECKER FARM ROAD SUITE 103, ROSELAND NJ, 07068. The company can be reached via phone at 973-532-8000 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

OTCMKTS:EMISEmisphere Technologies Stock Price, Forecast & News

Adding